Acorai, a Swedish-based medical device start-up, has announced endorsements from two major healthcare players as they prepare the Acorai Heart Monitor for regulatory submission and clinical use within the next 18 months.
Acorai is developing a first-of-its-kind, scalable medical device for non-invasive intracardiac pressure monitoring to improve heart failure management for more than 60 million patients worldwide. The Acorai Heart Monitor has clinically demonstrated accuracies equal to the invasive gold standards in a 200-patient feasibility study.
Investments from NHS-linked Kings Health Care Partners (KHP) and inclusion in the HealthTech Arkansas HeartX program support Acorai’s clinical studies within the UK and US healthcare systems. These studies will generate data across a broader population to increase the robustness and accuracies already demonstrated in the first feasibility study.
Filip Peters, Acorai’s CEO, said: “Investment from KHP Ventures and HealthTech Arkansas demonstrates that we are addressing a high unmet need within the heart failure space. Having partners like these, with a deep understanding of the complexities of bringing a medical device to market, allows us to de-risk our pathway towards commercialisation in 2024.”
Acorai will also expand its clinical studies to other US and European sites in 2023. The two investments from KHP and Healthtech Arkansas are crucial milestones as they demonstrate clinical and corporate endorsement for the development and product strategy of Acorai.